DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
CC-486 is an investigational drug.
There have been 27 clinical trials for CC-486. The most recent clinical trial was a Phase 1 trial, which was initiated on June 14th 2019.
The most common disease conditions in clinical trials are Lymphoma, Leukemia, and Preleukemia. The leading clinical trial sponsors are Celgene Corporation, Celgene, and National Cancer Institute (NCI).
There are twenty-two US patents protecting this investigational drug and one hundred and ninety-six international patents.
Recent Clinical Trials for CC-486
|A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)||AbbVie||Phase 1|
|A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)||Celgene||Phase 1|
|Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma||National Cancer Institute (NCI)||Phase 2/Phase 3|
Top disease conditions for CC-486
Top clinical trial sponsors for CC-486
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|CC-486||Get Started Free||Remote loading of sparingly water-soluble drugs into lipid vesicles||ZONEONE PHARMA, INC. (San Francisco, CA)||Get Started Free|
|CC-486||Get Started Free||Generation of muscle lineage cells and therapeutic uses thereof||GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA)||Get Started Free|
|CC-486||Get Started Free||Tumor-selective combination therapy||The Board of Regents of the University of Texas System (Austin, TX) The Board of Trustees of the University of Illinois. (Urbana, IL)||Get Started Free|
|CC-486||Get Started Free||Remote loading of sparingly water-soluble drugs into liposomes||ZONEONE PHARMA, INC. (San Francisco, CA)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|CC-486||Australia||AU2015301234||2034-08-04||Get Started Free|
|CC-486||Canada||CA2962709||2034-08-04||Get Started Free|
|CC-486||China||CN106999419||2034-08-04||Get Started Free|
|CC-486||European Patent Office||EP3177269||2034-08-04||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|